AAAAAA

   
Results: 1-25 | 26-39
Results: 1-25/39
Issues in cardiac intervention for UA/NSTEMI
Authors: Hod, HH Kleiman, NS Sequeira, RF Voipio-Pulkki, LM
Citation: Hh. Hod et al., Issues in cardiac intervention for UA/NSTEMI, EUR H J SUP, 3(J), 2001, pp. J32-J39
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Authors: Aronow, HD Topol, EJ Roe, MT Houghtaling, PL Wolski, KE Lincoff, AM Harrington, RA Califf, RM Ohman, EM Kleiman, NS Keltai, M Wilcox, RG Vahanian, A Armstrong, PW Lauer, MS
Citation: Hd. Aronow et al., Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study, LANCET, 357(9262), 2001, pp. 1063-1068
Abciximab readministration - Results of the ReoPro readministration registry
Authors: Tcheng, JE Kereiakes, DJ Lincoff, AM George, BS Kleiman, NS Sane, DC Cines, DB Jordan, RE Mascelli, MA Langrall, MA Damaraju, L Schantz, A Effron, MB Braden, GA
Citation: Je. Tcheng et al., Abciximab readministration - Results of the ReoPro readministration registry, CIRCULATION, 104(8), 2001, pp. 870-875
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT
Authors: Tardiff, BE Jennings, LK Harrington, RA Gretler, D Potthoff, RF Vorchheimer, DA Eisenberg, PR Lincoff, AM Labinaz, M Joseph, DM McDougal, MF Kleiman, NS
Citation: Be. Tardiff et al., Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT, CIRCULATION, 104(4), 2001, pp. 399-405
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention
Authors: Gilchrist, IC O'Shea, JC Kosoglou, T Jennings, LK Lorenz, TJ Kitt, MM Kleiman, NS Talley, D Aguirre, F Davidson, C Runyon, J Tcheng, JE
Citation: Ic. Gilchrist et al., Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention, CIRCULATION, 104(4), 2001, pp. 406-411
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes
Authors: Roffi, M Chew, DP Mukherjee, D Bhatt, DL White, JA Heeschen, C Hamm, CW Moliterno, DJ Califf, RA White, HD Kleiman, NS Theroux, P Topol, EJ
Citation: M. Roffi et al., Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with Non-ST-segment-elevation acute coronary syndromes, CIRCULATION, 104(23), 2001, pp. 2767-2771
Clinical pharmacology of higher dose eptifibatide in percutaneous coronaryintervention (the PRIDE study)
Authors: Tcheng, JE Talley, JD O'Shea, JC Gilchrist, IC Kleiman, NS Grines, CL Davidson, CJ Lincoff, AM Califf, RM Jennings, LK Kitt, MM Lorenz, TJ
Citation: Je. Tcheng et al., Clinical pharmacology of higher dose eptifibatide in percutaneous coronaryintervention (the PRIDE study), AM J CARD, 88(10), 2001, pp. 1097-1102
Dalteparin in combination with abciximab during percutaneous coronary intervention
Authors: Kereiakes, DJ Kleiman, NS Fry, E Mwawasi, G Lengerich, R Maresh, K Burkert, ML Aquilina, JW DeLoof, M Broderick, TM Shimshak, TM
Citation: Dj. Kereiakes et al., Dalteparin in combination with abciximab during percutaneous coronary intervention, AM HEART J, 141(3), 2001, pp. 348-352
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonistdoes not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction
Authors: Kleiman, NS Tracy, RP Talley, JD Sigmon, K Joseph, D Topol, EJ Califf, RM Kitt, M Ohman, EM
Citation: Ns. Kleiman et al., Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonistdoes not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction, J THROMB TH, 9(1), 2000, pp. 5-12
Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro
Authors: Kleiman, NS Graziadei, N Jordan, RE Lance, ET Fischer, A Maresh, K Edwards, A Mascelli, MA
Citation: Ns. Kleiman et al., Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro, J THROMB TH, 9(1), 2000, pp. 29-36
Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender - Pooled analysis from EPIC, EPILOG and EPISTENT trials
Authors: Cho, L Topol, EJ Balog, C Foody, JM Booth, JE Cabot, C Kleiman, NS Tcheng, JE Califf, R Lincoff, MA
Citation: L. Cho et al., Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender - Pooled analysis from EPIC, EPILOG and EPISTENT trials, J AM COL C, 36(2), 2000, pp. 381-386
Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000
Authors: Kleiman, NS Califf, RM
Citation: Ns. Kleiman et Rm. Califf, Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000, J AM COL C, 36(1), 2000, pp. 310-310
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial
Authors: Topol, CE Califf, RM Simes, RJ Van de Werf, F Diaz, R Paolasso, E Aylward, PE Keech, A Klein, W Piegas, L Tomov, I Armstrong, PW Widimsky, P Grande, P Halinen, M Vahanian, A Neuhaus, K Dimas, AP Preda, I Kristinsson, A Tzivoni, D Ardissino, D White, HD Madsen, S Sugrue, D Sadowski, Z Seabra-Gomes, R Apetrei, E Dalby, A Betriu, A Pfisterer, M Verheugt, F Fox, K Bates, ER Gibler, WB Granger, CB Harrington, RA Hochman, JS Holmes, DR Kleiman, NS Lee, KL Moliterno, DJ Newby, LK Ohman, EM Califf, R Newby, K Zillman, L Lee, K Lemons, P McCourt, B Campbell, C Tardiff, B Snapp, J Bassett, K Hodgson, P Hannan, K Kandzari, L Hawkins, S Hinman-Smith, E McDougal, M Raffetto, K Thompson, D Wehrle, T Ange, C Brown, R Grissom, G Heuckel, M McCall, J Pennachi, W Spychala, M Veasey, S Pullium, M Journey, T Quintero, K Mark, D Davidson-Ray, L Diner, L Nelson, C Sowers, C Webb, G Young, M Bhapkar, M Pacchiana, C Sparapani, R Tuttle, R Weaver, D Borzak, S Douthat, L Topol, E Moliterno, D Konczos, L Baishnab, R Baishnab, R Bakos, A Blashford, L Bratsch, J Brown, K Cadorini, E Carlson, J Clemmons, P DelValle, M Drabik, M Fu, G Gates, K Gibson, Y Heil, L Hill, N Klancar, R McHale, B Montague, E Pasca, N Pergi, L Randall, R Rosso, R Sankovich, K Smith, D Wisniewski, L Witkowski, M Zovkic, V Alexander, K Bhatt, D Brener, S Campbell, L Cho, L Cole, C Deedy, M Foody, J Gassler, J Ghaffari, S Haas, G Kapadia, S Lauer, M Lauer, MS Lincoff, M Lutton, S Marso, S Mukherjee, D Patel, V Penn, M Robbins, M Roe, M Sila, C Thamilarasan, M Wagner, G Armstrong, P Bestilny, S Van de Werf, F Budts, W Graux, S Luyten, A Simes, J Keech, A Kava, M Bower, T Chan, S Crampton, L Monro, C Nayak, M Parente, G Riley, V Wilton, D Aylward, P Dolan, S Thomas, C White, H Scott, M Frye, R Alpert, J Bertrand, M Ryan, T Fisher, L Asarch, L Smith, M Lim, L Bokslag, M Chiu, P Chung, J Collins, S Dougherty, C Guimaraes, D Hakim, Z Mathieson, J Montgomery, L Novotny, B Steiner, B Wittke, B
Citation: Ce. Topol et al., Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial, LANCET, 355(9201), 2000, pp. 337-345
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting
Authors: Marso, SP Bhatt, DL Roe, MT Houghtaling, PL Labinaz, M Kleiman, NS Dyke, C Simmoons, ML Califf, RM Harrington, RA Topol, EJ
Citation: Sp. Marso et al., Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting, CIRCULATION, 102(24), 2000, pp. 2952-2958
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition - Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Authors: Lincoff, AM Harrington, RA Califf, RM Hochman, JS Guerci, AD Ohman, EM Pepine, CJ Kopecky, SL Kleiman, NS Pacchiana, CM Berdan, LG Kitt, MM Simoons, ML Topol, EJ
Citation: Am. Lincoff et al., Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition - Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 102(10), 2000, pp. 1093-1100
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
Authors: Kleiman, NS Lincoff, AM Flaker, GC Pieper, KS Wilcox, RG Berdan, LG Lorenz, TJ Cokkinos, DV Simoons, ML Boersma, E Topol, EJ Califf, RM Harrington, RA
Citation: Ns. Kleiman et al., Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes, CIRCULATION, 101(7), 2000, pp. 751-757
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction - Results from TIMI (thrombolysis in myocardial infarction) 14
Authors: Coulter, SA Cannon, CP Ault, KA Antman, EM Van de Werf, F Adgey, AJJ Gibson, CM Giugliano, RP Mascelli, MA Scherer, J Barnathan, ES Braunwald, E Kleiman, NS
Citation: Sa. Coulter et al., High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction - Results from TIMI (thrombolysis in myocardial infarction) 14, CIRCULATION, 101(23), 2000, pp. 2690-2695
Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty
Authors: Fredrickson, BJ Turner, NA Kleiman, NS Graziadei, N Maresh, K Mascelli, MA Effron, MB McIntire, LV
Citation: Bj. Fredrickson et al., Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty, CIRCULATION, 101(10), 2000, pp. 1122-1129
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction
Authors: Crenshaw, BS Granger, CB Birnbaum, Y Pieper, KS Morris, DC Kleiman, NS Vahanian, A Califf, RM Topol, EJ
Citation: Bs. Crenshaw et al., Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction, CIRCULATION, 101(1), 2000, pp. 27-32
Redefining medical treatment in the management of unstable angina
Authors: Braunwald, E Califf, RM Cannon, CP Fox, KAA Fuster, V Gibler, WB Harrington, RA King, SB Kleiman, NS Theroux, P Topol, EJ Van de Werf, F White, HD Willerson, JT
Citation: E. Braunwald et al., Redefining medical treatment in the management of unstable angina, AM J MED, 108(1), 2000, pp. 41-53
A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb)
Authors: Batchelor, WB Granger, CB Kleiman, NS Phillips, HR Ellis, SG Betriu, A Criger, DA Stebbins, AL Topol, EJ Califf, RM
Citation: Wb. Batchelor et al., A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb), AM J CARD, 85(6), 2000, pp. 692-697
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions
Authors: Kleiman, NS Grazeiadei, N Maresh, K Taylor, RJ Frederick, B Lance, ET Effron, MB Jordan, RE Mascelli, MA
Citation: Ns. Kleiman et al., Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions, AM HEART J, 140(3), 2000, pp. 492-501
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab
Authors: Mascelli, MA Kleiman, NS Marciniak, SJ Damaraju, L Weisman, HF Jordan, RE
Citation: Ma. Mascelli et al., Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab, AM HEART J, 139(4), 2000, pp. 696-703
Safety issues surrounding use of platelet GP IIb/IIIa antagonists: reversibility and readministration
Authors: Kleiman, NS Tcheng, JE
Citation: Ns. Kleiman et Je. Tcheng, Safety issues surrounding use of platelet GP IIb/IIIa antagonists: reversibility and readministration, EUR H J SUP, 1(E), 1999, pp. E36-E42
Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
Authors: Mickelson, JK Ali, MN Kleiman, NS Lakkis, NM Chow, TW Hughes, BJ Smith, CW
Citation: Jk. Mickelson et al., Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty, J AM COL C, 33(1), 1999, pp. 97-106
Risultati: 1-25 | 26-39